[FOR RELEASE September 4, 2014 China Biologic Completes Transaction to Acquire Additional Equity Stake in Guizhou Taibang BEIJING, China – September 4, 2014 – Additional information about this transaction can be found in the Company’s previous release and 8-K filing with the SEC on August 25, 2014. About China Biologic Products, Inc. China Biologic is a leading plasma-based biopharmaceutical company] []
[FOR RELEASE September 4, 2014 China Biologic Completes Transaction to Acquire Additional Equity Stake in Guizhou Taibang BEIJING, China – September 4, 2014 – Additional information about this transaction can be found in the Company’s previous release and 8-K filing with the SEC on August 25, 2014. About China Biologic Products, Inc. China Biologic is a leading plasma-based biopharmaceutical company] []
[Registered Equity Purchase Agreement Agreement Purchaser Seller This Registered Equity Purchase Agreement (this “ WHEREAS Target Company WHEREAS Capital Increase WHEREAS Target Equities WHEREAS NOW THEREFORE Section 2 Sale of Equity Interests Sale of Equity Interests 2.1 Equity Transfer Subject to the terms and conditions hereunder and satisfaction of such terms and conditions, the Seller agrees to sell to the] [Equity Exchange Agreement Agreement Guiyang Dalin Guizhou Eakan This Equity Exchange Agreement (this “ WHEREAS Guizhou Taibang WHEREAS Capital Increase WHEREAS Taibang Equities WHEREAS Acquisition SPV SPV Equities WHEREAS NOW THEREFORE Section 2 Equity Exchange Equity Exchange 2.1 Guizhou Eakan agrees to sell the Taibang Equities in exchange for the SPV Equities held by Guiyang Dalin (the “ 2.2 The] [Unregistered Equity Purchase Agreement Agreement Purchaser Seller This Unregistered Equity Purchase Agreement (this “ WHEREAS Capital Increase Target Company Shareholders Resolutions Unregistered Equities Contingent Claims Target Interests WHEREAS NOW THEREFORE Section 2 Sale of the Target Interests Sale of the Target Interests 2.1 Equity Transfer Purchase Price 2.1.1 Subject to the terms and conditions hereunder and the satisfaction of such] [FOR RELEASE August 25, 2014 China Biologic to Increase Equity Stake in Guizhou Taibang BEIJING, China – August 25, 2014 – Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, “Increasing our ownership position in Guizhou Taibang is a significant development for China Biologic. Since acquiring the majority stake in 2008, we have been focusing on] []
[Registered Equity Purchase Agreement Agreement Purchaser Seller This Registered Equity Purchase Agreement (this “ WHEREAS Target Company WHEREAS Capital Increase WHEREAS Target Equities WHEREAS NOW THEREFORE Section 2 Sale of Equity Interests Sale of Equity Interests 2.1 Equity Transfer Subject to the terms and conditions hereunder and satisfaction of such terms and conditions, the Seller agrees to sell to the] [Equity Exchange Agreement Agreement Guiyang Dalin Guizhou Eakan This Equity Exchange Agreement (this “ WHEREAS Guizhou Taibang WHEREAS Capital Increase WHEREAS Taibang Equities WHEREAS Acquisition SPV SPV Equities WHEREAS NOW THEREFORE Section 2 Equity Exchange Equity Exchange 2.1 Guizhou Eakan agrees to sell the Taibang Equities in exchange for the SPV Equities held by Guiyang Dalin (the “ 2.2 The] [Unregistered Equity Purchase Agreement Agreement Purchaser Seller This Unregistered Equity Purchase Agreement (this “ WHEREAS Capital Increase Target Company Shareholders Resolutions Unregistered Equities Contingent Claims Target Interests WHEREAS NOW THEREFORE Section 2 Sale of the Target Interests Sale of the Target Interests 2.1 Equity Transfer Purchase Price 2.1.1 Subject to the terms and conditions hereunder and the satisfaction of such] [FOR RELEASE August 25, 2014 China Biologic to Increase Equity Stake in Guizhou Taibang BEIJING, China – August 25, 2014 – Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of China Biologic, commented, “Increasing our ownership position in Guizhou Taibang is a significant development for China Biologic. Since acquiring the majority stake in 2008, we have been focusing on] []
[FOR RELEASE August 5, 2014 China Biologic Reports Financial Results for the Second Quarter of 2014 2Q14 Total Sales Increase 12.1% to $60.1Million 2Q14 Operating Margin Increases to 48.1% from 2Q14 Non-GAAP Net Income Increases 17.9% to $20.5 Million BEIJING, China – August 5, 2014 – Second Quarter 2014 Financial Highlights · Total sales · Gross profit · Income from] []
[FOR RELEASE August 5, 2014 China Biologic Reports Financial Results for the Second Quarter of 2014 2Q14 Total Sales Increase 12.1% to $60.1Million 2Q14 Operating Margin Increases to 48.1% from 2Q14 Non-GAAP Net Income Increases 17.9% to $20.5 Million BEIJING, China – August 5, 2014 – Second Quarter 2014 Financial Highlights · Total sales · Gross profit · Income from] []
[] [STATE OF DELAWARE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHINA BIOLOGIC PRODUCTS, INC. Corporation China Biologic Products, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ A. The name of the Corporation is China Biologic Products, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of] [THIRD AMENDED AND RESTATED BYLAWS OF CHINA BIOLOGIC PRODUCTS, INC. (the “Corporation”) Adopted on June 20, 2014 ARTICLE I OFFICES Registered Office Certificate of Incorporation Section 1.01. Other Offices Board of Directors Board Section 1.02. ARTICLE II MEETINGS OF STOCKHOLDERS Annual Meeting Section 2.01. Voting List Section 2.02. Special Meeting Section 2.03. Advance Notice Procedures Section 2.04. Advance Notice of] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
[] [STATE OF DELAWARE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CHINA BIOLOGIC PRODUCTS, INC. Corporation China Biologic Products, Inc., a corporation organized and existing under the laws of the State of Delaware (the “ A. The name of the Corporation is China Biologic Products, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of] [THIRD AMENDED AND RESTATED BYLAWS OF CHINA BIOLOGIC PRODUCTS, INC. (the “Corporation”) Adopted on June 20, 2014 ARTICLE I OFFICES Registered Office Certificate of Incorporation Section 1.01. Other Offices Board of Directors Board Section 1.02. ARTICLE II MEETINGS OF STOCKHOLDERS Annual Meeting Section 2.01. Voting List Section 2.02. Special Meeting Section 2.03. Advance Notice Procedures Section 2.04. Advance Notice of] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
